254 related articles for article (PubMed ID: 21303791)
21. Splenomegaly in FOLFOX-naïve stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy.
Miura K; Nakano H; Sakurai J; Kobayashi S; Koizumi S; Arai T; Shimamura T; Makizumi R; Yamada K; Miyajima N; Otsubo T; Koike J
Int J Clin Oncol; 2011 Jun; 16(3):257-63. PubMed ID: 21243394
[TBL] [Abstract][Full Text] [Related]
22. Interstitial pneumonia during bevacizumab-based chemotherapy for colorectal cancer.
Tamura S; Kusaba H; Kubo N; Ijichi K; Tsuchihashi K; Komoda M; Uchino K; Ariyama H; Akashi K; Baba E
Med Oncol; 2014 Mar; 31(3):856. PubMed ID: 24477650
[TBL] [Abstract][Full Text] [Related]
23. [The development of the first line treatment of metastatic colorectal cancer (mCRC)].
Landherr L; Nagykálnai T
Magy Onkol; 2009 Sep; 53(3):237-46. PubMed ID: 19793687
[TBL] [Abstract][Full Text] [Related]
24. [Bevacizumab in combination with mFOLFOX6 or FOLFIRI for previously treated metastatic colorectal cancer].
Koyama M; Murata A; Kimura Y; Sakamoto Y; Morohashi H; Kimura N; Gasa F; Sato J; Terui K; Awatsu A; Hakamada K
Gan To Kagaku Ryoho; 2010 Jun; 37(6):1069-73. PubMed ID: 20567110
[TBL] [Abstract][Full Text] [Related]
25. [Evaluation of bevacizumab for advanced colorectal cancer].
Naito M; Hoshino S; Noda N; Nakano M; Matsuo K; Yamauchi Y; Shinohara T; Tanaka S; Yamashita Y
Gan To Kagaku Ryoho; 2010 Jan; 37(1):83-8. PubMed ID: 20087037
[TBL] [Abstract][Full Text] [Related]
26. FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer.
Giusti RM; Cohen MH; Keegan P; Pazdur R
Oncologist; 2009 Mar; 14(3):284-90. PubMed ID: 19282350
[TBL] [Abstract][Full Text] [Related]
27. [Investigation of FOLFIRI/FOLFOX (+/-bevacizumab) therapy for patients with metastatic colorectal cancer in our hospital].
Hosoda K; Aoki M; Kido H; Natsu K; Tamura H; Kojima M; Amemiya T; Kamoshida T
Gan To Kagaku Ryoho; 2010 May; 37(5):841-5. PubMed ID: 20495313
[TBL] [Abstract][Full Text] [Related]
28. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L
J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
[TBL] [Abstract][Full Text] [Related]
30. Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802).
Suenaga M; Nishina T; Mizunuma N; Yasui H; Ura T; Denda T; Ikeda J; Esaki T; Nishisaki H; Takano Y; Sugiyama Y; Muro K
BMC Cancer; 2015 Mar; 15():176. PubMed ID: 25884814
[TBL] [Abstract][Full Text] [Related]
31. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
Dohn LH; Jensen BV; Larsen FO
Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495
[No Abstract] [Full Text] [Related]
32. 5-fluorouracil, leucovorin and oxaliplatin plus bevacizumab in the first-line treatment of metastatic colorectal cancer: a single-institute study.
Bir A; Tan W; Wilding GE; Lombardo J; Fakih MG
Oncology; 2007; 72(1-2):4-9. PubMed ID: 17971679
[TBL] [Abstract][Full Text] [Related]
33. Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer.
Vaidyanathan G; Groman A; Wilding G; Fakih MG
Oncology; 2010; 79(1-2):67-71. PubMed ID: 21071992
[TBL] [Abstract][Full Text] [Related]
34. A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.
Wainberg ZA; Messersmith WA; Peddi PF; Kapp AV; Ashkenazi A; Royer-Joo S; Portera CC; Kozloff MF
Clin Colorectal Cancer; 2013 Dec; 12(4):248-54. PubMed ID: 24075777
[TBL] [Abstract][Full Text] [Related]
35. [Metastatic colorectal cancer: adjournments from ESMO 2006].
Bonetti A; Cascinu S; Falcone A; Maiello E; Zaniboni A; Aschele C
Tumori; 2006; 92(6):1-12. PubMed ID: 17262903
[No Abstract] [Full Text] [Related]
36. First-line therapy for metastatic colorectal carcinoma: modified FOLFOX4 or FOLFIRI-bevacizumab.
Odabas H; Ozdemir N; Abali H; Oksuzoglu B; Isik M; Uncu D; Cihan S; Seker M; Zengin N
J BUON; 2011; 16(2):247-52. PubMed ID: 21766493
[TBL] [Abstract][Full Text] [Related]
37. FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer.
Petrioli R; Paolelli L; Marsili S; Civitelli S; Francini E; Cioppa T; Roviello F; Nettuno R; Intrivici C; Tanzini G; Lorenzi M; Francini G
Oncology; 2006; 70(5):345-50. PubMed ID: 17179728
[TBL] [Abstract][Full Text] [Related]
38. [Recent results of irinotecan therapy in colorectal cancer].
Láng I; Hitre E
Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
[TBL] [Abstract][Full Text] [Related]
39. [A case of interstitial lung diseases in patient treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX)].
Nakagawa M; Hamada A; Yoshihara Y; Ishizaka T; Fukushima M; Takahashi N; Sawada R; Mukai J
Gan To Kagaku Ryoho; 2011 Feb; 38(2):317-20. PubMed ID: 21368504
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]